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Background: Health-related quality of life is often collected in clinical studies, and forms a cornerstone of economic
evaluation. This study had two objectives, firstly to report and compare pre- and post-progression health state utilities
in advanced melanoma when valued by different methods and secondly to explore the validity of progression-based
health state utility modelling compared to modelling based upon time to death.
Methods: Utilities were generated from the ipilimumab MDX010-20 trial (Clinicaltrials.gov Identifier: NCT00094653)
using the condition-specific EORTC QLQ-C30 (via the EORTC-8D) and generic SF-36v2 (via the SF-6D) preference-based
measures. Analyses by progression status and time to death were conducted on the patient-level data from the
MDX010-20 trial using generalised estimating equations fitted in Stata®, and the predictive abilities of the two
approaches compared.
Results: Mean utility showed a decrease on disease progression in both the EORTC-8D (0.813 to 0.776) and the
SF-6D (0.648 to 0.626). Whilst higher utilities were obtained using the EORTC-8D, the relative decrease in utility on
progression was similar between measures. When analysed by time to death, both EORTC-8D and SF-6D showed
a large decrease in utility in the 180 days prior to death (from 0.831 to 0.653 and from 0.667 to 0.544, respectively).
Compared to progression status alone, the use of time to death gave similar or better estimates of the original data
when used to predict patient utility in the MDX010-20 study. Including both progression status and time to death
further improved model fit. Utilities seen in MDX010-20 were also broadly comparable with those seen in the literature.
Conclusions: Patient-level utility data should be analysed prior to constructing economic models, as analysis solely by
progression status may not capture all predictive factors of patient utility and time to death may, as death approaches,
be as or more important. Additionally this study adds to the body of evidence showing that different scales lead to
different health state values. Further research is needed on how different utility instruments (the SF-6D, EORTC-8D and
EQ-5D) relate to each other in different disease areas.
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Utilities are commonly used to provide a preference
weighted estimate of health-related quality of life (HRQL)
benefits provided by treatments in the context of assessing
the cost effectiveness of those treatments. They are there-
fore crucial to health technology assessment when using a
cost per quality-adjusted life year framework. Utility values
can be generated in several ways, including generic* Correspondence: ahatswell@bresmed.co.uk
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based measures, vignettes and directly-elicited patient util-
ity values. However, the use of different instruments (in
the same population) has been shown to produce different
results, with a range of utility measures having been used
in oncology [1-3].
Health-state classifications for economic modelling are
frequently based on a patient’s progression status, often
the primary endpoint in oncology trials (including mel-
anoma). Melanoma is a form of skin cancer and if iden-
tified early the prognosis is generally good [4]; however,l Ltd. This is an Open Access article distributed under the terms of the Creative
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treatment are limited. In oncology progression is gener-
ally accepted to be important for both disease burden
and HRQL, with a delay in progression an objective of
treatment. During our investigation we sought clinical
opinion, which indicated that there is a decline in HRQL
in the final months of life of advanced melanoma pa-
tients, which may not be appropriately captured solely
through the use of progression-based heath states.
We therefore undertook the study reported here with
two objectives in mind: firstly to report and compare pre-
and post-progression health state utilities in advanced mel-
anoma, when generated using different methods - via
the EORTC (European Organisation for Research and
Treatment of Cancer, Brussels, Belgium), and the SF-36
(QualityMetric, Lincoln, USA); secondly, to explore the
validity, in advanced melanoma, of progression-based
health-state utility modelling compared to modelling
based upon time to death health states.
Methods
Regulatory approval for ipilimumab in advanced (unre-
sectable or metastatic) melanoma was based on data from
the Phase III clinical trial MDX010-20 (Clinicaltrials.gov
Identifier: NCT00094653), conducted in accordance with
the Declaration of Helsinki, and the laws and regulatory
requirements of the countries where the research was per-
formed. Patients (or their legal representatives) were re-
quired to give written informed consent before enrolment,
and the protocol approved by institutional review boards
at each of the 125 sites involved. All patients enrolled
in to the study had unresectable advanced melanoma
(disease that had spread from the area of skin where it
originated), at stage III (the disease having spread to re-
gional lymph nodes, but no evidence of distant metas-
tases), or stage IV (the disease having spread to distant
lymph nodes, or other organs).
Trial data were extracted from the study database
using SAS® (SAS, Cary, USA) and analysed in Stata® 12.0
(StataCorp, Texas, USA) [5]. The trial included 676 pa-
tients, randomised 3:1:1 to ipilimumab + gp100, ipilimu-
mab only, or gp100 only. Gp100 is an experimental
peptide-based vaccine, with few side effects, later shown
to be ineffective in increasing overall survival. Approxi-
mately 60% of patients were male, with the majority of
patients having Eastern Cooperative Oncology Group
(ECOG) performance status 0 (55%) or 1 (43%). All pa-
tients had received prior systemic therapy for their ad-
vanced melanoma – a complete description of the study
is available in Hodi et al., 2010 [5]. In the study, patients
were asked to complete both the EORTC QLQ-C30 and
SF-36v2 questionnaires on receipt of the first dose of
treatment, at the end of treatment and 12 weeks after
treatment. These time points were pre-specified for thefirst 4 doses, however beyond this point quality of life
instruments were only administered when patients re-
ceived retreatment.
The EORTC QLQ-C30, administered in MDX010-20,
is frequently used in oncology clinical trials as it cap-
tures many of the symptoms commonly seen in cancer
patients, such as nausea, pain and fatigue, as well as gen-
eric aspects of function (including physical, emotional
and role). Rowen et al. generated the EORTC-8D – a
condition-specific preference-based measure derived from
the EORTC QLQ-C30 [6]. A sample of health states were
valued by 350 members of the UK general public using
time trade-off, and these values were modelled to produce
utilities for all health states. In order to generate EORTC-
8D utilities from the EORTC QLQ-C30 results, Model 3
from the mapping by Rowen et al. was used [6]. In the
MDX010-20 trial, this questionnaire was completed by
616 patients (1,237 observations).
The SF-6D (derived from the SF-36 or SF-12) is a
widely-used generic preference-based measure of HRQL,
which has been valued by 611 members of the UK gen-
eral public using standard-gamble methodology for a
sample of health states. Several methods are available to
convert SF-36 results to SF-6D utilities; this study uses
the most recent non-parametric Bayesian method [7-9].
In the MDX010-20 trial, 599 patients completed the SF-
36 (1,205 observations).
The majority of HRQL questionnaires (both EORTC
QLQ-C30 and SF-36) were completed within the first
24 weeks of the trial (before and after patients were ad-
ministered their initial course of ipilimumab), though
observations are available for up to 4 years (5% of pa-
tients completed questionnaires after 12 months if re-
ceiving retreatment). Where multiple observations were
available for a patient, all observations were included in
calculations. The level of non-response to the EORTC
QLQ-C30 and SF-36 was low within the study, at 7.8%
and 11.4%, respectively. We did not attempt to impute
missing values, as their low number means they would
be unlikely to affect the results of the study, nevertheless
this remains a limitation of the work performed.
To provide context to the analysis, a literature search
was completed in May 2013 for utilities in advanced
melanoma (including previously untreated disease) with
at least 30 patients in the study. This search included
the Medline, Embase, NHS Health Economic Evaluation
Database, Cochrane Health Technology Assessment,
Database of Abstracts of Reviews of Effect (DARE),
Cumulative Index to Nursing and Allied Health Litera-
ture (CINAHL) and Econlit databases.
Progression status versus time to death
In order to ascertain whether the time to a patient’s death
influenced their quality of life, a series of regression
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groups based on their time to death after the HRQL meas-
urement was taken. The groups were based on clinician
feedback on the phases of life generally seen in patients
before death (over 180 days, 120–180 days, 90–120 days,
60–90 days, 30–60 days, and under 30 days). Patient time
to death was then extracted from the study database and
grouped according to these time points.
Where a patient was still alive at the end of the study,
the final measurement point was used as the time of
death. In 91% of cases where censoring occurred, this
put patients in the health state furthest from death
(>180 days), with only 2.9% of EORTC-8D and 2.5% of
SF-6D of observations categorised as censored before
the 180 days from death time point. Given this low level
of censoring models accounting for censoring were not
required to be fitted.
The models fitted to the data were generalised estimat-
ing equation (GEE) random effects models to account
for correlation between repeated measurements from
the same individuals. GEE models were chosen instead
of generalised linear mixed models, in order to produce
population averages as required for the purpose of
health technology assessment and economic modelling.
To compare model fit the mean absolute error and the
root mean squared error were calculated, with tests for
significance using Student’s t-test with a p-value of 0.05.
Results
EORTC-8D versus SF-6D values
In all treatment groups and disease states, mean utilities
generated from the EORTC-8D were significantly higher
than those seen with the SF-6D (p < 0.001), the difference
in the values being shown in Figure 1. Of 807 measure-
ments of HRQL at the same time-point for both instru-
ments, the EORTC-8D utility was higher on 777 occasions
(Figure 2). SF-6D values appear to be more concentrated
around the mean: 28% of the SF-6D utilities were within
5% of the mean value, compared to only 13% of the
EORTC-8D utilities, though no statistical tests were per-
formed to estimate this formally. Despite the differences
in magnitude between the two methods, the change in
utility on disease progression was similar with both the
EORTC-8D utilities (−4.6%) and SF-6D utilities (−3.3%).
Progression status versus time to death
Three models were fitted to the patient-level data for
both EORTC-8D and SF-6D in order to predict patient
utility, these are shown in Table 1. Model 1 used pro-
gression status alone to predict utility, Model 2 used
time to death health states only, and Model 3 used both
progression status and time to death health states.
Model 1 showed that patients experienced a reduction
in utility of 0.048 (standard error 0.007) followingprogression using the EORTC-8D and a reduction in
utility of 0.030 (standard error 0.005) using the SF-6D.
Clinician feedback following discussion of these results
was that patients would be treated according to their ex-
pected survival period. These health states were specified
by clinicians and then used in Model 2 and Model 3, as
described in the Methods section.
Model 2 used time to death as a categorical variable,
grouping patients by survival period, and showed that
patient utility fell consistently as a patient approached
death in both EORTC-8D and SF-6D utilities. This
slightly improved the predictive power of the regression
in the EORTC-8D, and slightly worsened it in the SF-
6D. Model 3 included whether a patient had progressed
as a dummy variable, and their time to death at the
point the measurement was taken, and improved on the
time to death model for both EORTC-8D and SF-6D.
The results of this time to death including progression
model showed a similar pattern of decline in utility as a
patient approaches death, with an additional decrement
to utility if a patient had experienced disease progres-
sion. The fit of each of the models can be seen in Table 2,
which compares predicted values for each of the health
state based models, to observed values in those patient
groups. Model fit can also been seen in Table 1, where
the mean absolute error and root mean squared error
are given for all values, and also reported separately for
approximately equal segments of the utility distributions,
which allows a comparison of model fit across the distri-
bution of utility values.
Models including death as a continuous variable, or
restricting analysis only to patients who died in the
study period did not produce substantially different
results (results not presented). Adding further clinically-
relevant variables (treatment assignment, prior Interleukin-
2 usage, age, ECOG status or melanoma stage: all
measured at baseline) did not result in significant coef-
ficients or increase the predictive power of the model.
These additional variables were therefore not included in
the final models, but are provided in Additional file 1:
Table S1 for completeness. Fitting models separately for
pre- and post-progression utilities when including time to
death yielded similar coefficients for pre-progression and
post-progression - the consistency of parameter estimates
and standard errors across models when including pro-
gression status (moving from Model 2 to Model 3) indi-
cate low levels of multi-collinearity between progression
status and time to death.
Utility remained high until approximately 180 days be-
fore death with both the EORTC-8D and SF-6D (0.840
and 0.672), similar to values seen in the general popula-
tion (0.80 for a 55–64 year old using the EQ-5D) [10].
From this point onwards HRQL continually decreased,
with the final 30 days of life having the largest decrease
Figure 1 Plot of EORTC-8D and SF-6D patient reported utilities by progression status and time to death in the MDX010-20 trial.
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measured at identical time points, by progression status.compared to patients 180 days or more from death
(EORTC-8D −0.189 and SF-6D −0.141) (Table 1). All time
based health state coefficients were significantly lower
than the 180 days before death health state (p < 0.001 for
all coefficients), for both EORTC-8D and SF-6D.
For the EORTC-8D, the time to death health state ap-
proach provides a more accurate estimate of patient util-
ity than progression status according to the mean
absolute error and root mean squared error (particularly
for values further from the mean). Using both factors
further increases accuracy of estimates. For the SF-6D,
using time to death as health states resulted in predic-
tions on average slightly worse than the progression
based model. Using both time to death and progression
improved the accuracy of estimates compared to time to
death alone, though did not provide as good a prediction
as progression only.
Discussion
EORTC-8D versus SF-6D utility values
No studies are presently available that directly com-
pare the EORTC-8D to the SF-6D. We observed that
EORTC-8D utilities were higher than SF-6D utilities in
both the pre- and post-progression states. This differ-
ence in utilities derived from the two preference-based
measures adds to the body of literature that suggests dif-
ferent measures may produce different utilities. EQ-5D,
Table 1 Results of regression analyses based for models, including goodness-of-fit statistics
EORTC-8D derived results
Progression (model 1) Time to death (model 2) Progression + time to death (model 3)
Constant 0.803 0.831 0.837
(SE) (0.006) (0.006) (0.006)
Progression −0.048 −0.029
(SE) (0.007) (0.007)
120 - 179 days to death −0.060 −0.059
(SE) (0.012) (0.012)
90 - 119 days to death −0.068 −0.065
(SE) (0.015) (0.015)
60 - 89 days to death −0.112 −0.106
(SE) (0.016) (0.016)
30 - 59 days to death −0.153 −0.142
(SE) (0.015) (0.015)
Under 30 days to death −0.178 −0.165
(SE) (0.019) (0.019)
MAE RMSE MAE RMSE MAE RMSE
All values 0.119 0.145 0.108 0.132 0.108 0.132
0.9 < EORTC-8D ≤ 1 (n = 354) 0.167 0.171 0.137 0.145 0.139 0.147
0.8 < EORTC-8D≤ 0.9 (n = 280) 0.056 0.066 0.046 0.063 0.048 0.064
0.65 < EORTC-8D ≤ 0.8 (n = 332) 0.061 0.073 0.077 0.088 0.074 0.086
0.0 < EORTC-8D≤ 0.65 (n = 174) 0.235 0.246 0.206 0.225 0.204 0.222
SF-6D derived results
Progression (model 1) Time to death (model 2) Progression + time to death (model 3)
Constant 0.642 0.667 0.670
(SE) (0.006) (0.005) (0.005)
Progression −0.030 −0.016
(SE) (0.005) (0.006)
120 - 179 days to death −0.050 −0.050
(SE) (0.010) (0.010)
90 - 119 days to death −0.059 −0.057
(SE) (0.013) (0.013)
60 - 89 days to death −0.089 −0.085
(SE) (0.014) (0.013)
30 - 59 days to death −0.119 −0.113
(SE) (0.013) (0.013)
Under 30 days to death −0.134 −0.126
(SE) (0.016) (0.016)
MAE RMSE MAE RMSE MAE RMSE
All values 0.091 0.124 0.102 0.134 0.101 0.133
0.75 < SF-6D≤ 1 (n = 201) 0.201 0.210 0.199 0.212 0.199 0.212
0.65 < SF-6D≤ 0.75 (n = 228) 0.050 0.057 0.047 0.065 0.047 0.065
0.55 < SF-6D≤ 0.65 (n = 435) 0.028 0.037 0.051 0.058 0.049 0.057
0 < SF-6D≤ 0.55 (n = 208) 0.159 0.174 0.175 0.194 0.173 0.192
SE = standard error, MAE =mean absolute error, RMSE = root mean squared error.
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Table 2 Predicted versus observed mean utility values for models based on health states
Model Health state EORTC-8D SF-6D
Predicted Observed Predicted Observed
Model 1 Pre-progression 0.803 0.813 0.642 0.648
Post-progression 0.755 0.776 0.612 0.626
Model 2 180 or more days to death 0.831 0.840 0.667 0.672
120 - 179 days to death 0.771 0.767 0.616 0.610
90 - 119 days to death 0.763 0.756 0.613 0.600
60 - 89 days to death 0.720 0.723 0.585 0.574
30 - 59 days to death 0.679 0.670 0.557 0.541
Under 30 days to death 0.653 0.651 0.544 0.531
Model 3 Pre-progression
180 or more days to death 0.837 0.848 0.670 0.677
120 - 179 days to death 0.779 0.777 0.620 0.615
90 - 119 days to death 0.772 0.759 0.613 0.591
60 - 89 days to death 0.731 0.737 0.585 0.588
30 - 59 days to death 0.695 0.690 0.557 0.554
Under 30 days to death 0.672 0.629 0.544 0.518
Post-progression
180 or more days to death 0.808 0.820 0.654 0.661
120 - 179 days to death 0.749 0.742 0.614 0.595
90 - 119 days to death 0.743 0.750 0.613 0.623
60 - 89 days to death 0.702 0.693 0.585 0.547
30 - 59 days to death 0.665 0.643 0.507 0.521
Under 30 days to death 0.642 0.675 0.534 0.547
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has been shown to produce different utilities to SF-6D
(both higher and lower) in rheumatoid arthritis, consti-
pation and herniated discs [1-3,11].
A potential explanation for the difference in utilities
generated by the EORTC-8D is the classification system
used - this was originally derived using a multiple-
myeloma dataset [6]. When compared to the original
data, patients within the MDX010-20 dataset were more
likely to respond that they have the best level of health,
and less likely to report that they have the lowest level
of health for the physical, role functioning, and pain di-
mensions, than those from the EORTC-8D source data-
set. Although this does not in itself mean that the
classification system is not appropriate, further research
is encouraged to investigate whether the EORTC-8D has
desirable psychometric properties when applied to other
cancers.
Investigation of the properties of EORTC-8D- is particu-
larly important as the EORTC QLQ-C30 is a frequently-
used measure in oncology clinical trials, therefore utilities
from the EORTC-8D will often be available, whereas a
generic instrument (such as the SF-36 or EQ-5D) may not
be included in a study. Equally, for health technologyassessment purposes, it is likely to be important to under-
stand how the EORTC-8D relates to the SF-6D, Health
Utilities Index 3 (HUI-3) and, most notably, the EQ-5D
(the preferred measure of the National Institute of Health
and Care Excellence [NICE], and most frequently used
utility measure in health technology assessment studies
internationally) [12-14]. At present two studies are avail-
able comparing the EORTC-8D and EQ-5D, though only
in two types of cancer [13,15], however there is the poten-
tial for further analyses from a recently completed study
of dabrafenib compared to dacarbazine in advanced mel-
anoma, the BREAK-3 study, as this included both
EORTC-8D and EQ-5D [16].
Patient derived data compared to published utility values
The literature reviews identified four studies reporting
utilities in advanced melanoma. A mapping study by
Askew et al. reported a utilities of 0.85 for stage III melan-
oma (n = 100) and 0.86 for stage IV melanoma (n = 102).
[17] Dixon et al., in a trial of interferon-alpha compared to
placebo, collected EQ-5D over time, increasing from 0.76
at baseline (n = 111), to 0.77 at 3 months (n = 80), 0.82
at 12 months (n = 66), and finally to 0.83 at 24 months
(n = 31) [18]; personal communication with the author.
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scriptions of health states that are valued by the general
public) – one based in Australia/UK (n = 77/63) pub-
lished by Beusterien et al. [19], and one based in
Canada (n = 87). [20] These types of studies are often
used in health-state valuation for cost-effectiveness
analyses [21-23], especially when patient derived util-
ities are not available [24]. In the two vignette studies,
members of the public were asked to value partial re-
sponse, giving values of 0.85 and 0.84 in Australia/UK
and Canada, stable disease (0.77 and 0.79), progressive
disease (0.59 and 0.55), and best supportive care (0.59
and 0.54).
The values seen in MDX010-20 were broadly compar-
able to the values used in the published literature. Al-
though much higher than utilities typically seen in
advanced cancer [25], that values in multiple studies are
similar may indicate that patients with advanced melan-
oma exhibit HRQL similar to age-matched members of
the general population [10]. Of particular interest are
the values seen in Dixon et al., which showed the quality
of life of patients to increase the longer patients were in
the study, potentially indicating a link between proximity
to death, and low HRQL.
Progression versus time to death approach
Previous reviews have provided evidence for a positive
relationship between HRQL measures and the survival
duration of cancer patients [26,27]. A recent review
identified three studies in either advanced or metastatic
melanoma, all of which show either overall HRQL or
certain domains of HRQL to be predictive of survival
[28]. The analysis we have performed is therefore con-
sistent with this body of work and attempts to quantify
this relationship.
Utilities generated by both the EORTC-8D and SF-6D
showed a substantial decrease in utility in the final
180 days before a patient’s death. This was consistent
across measures and regression models, and, based on
clinician feedback it is possible that this is the case for
all metastatic melanoma patients. However, further re-
search is required using different datasets to establish
whether this is the case.
Progression status is a standard primary endpoint used
in clinical trials to define efficacy, and as such has been
the obvious choice for defining health states in cost-
effectiveness modelling. Oncology models are frequently
based on area under the curve models with three health
states (pre-progression, post-progression and death), with
transitions driven by parametric curves. However, our re-
search suggests that this approach may not be suitable to
model patients’ HRQL if disease progression is not closely
related to HRQL. In this case additional health states may
need to be added to model the path of HRQL.If this pattern of HRQL being linked to survival is re-
peated in other oncology areas, it may be better to re-
place the current standard method of progression-based
utilities, with analysis on a case-by-case basis - including
investigation of alternative explanations for HRQL de-
creases (for example a time to event based approach).
Designers of oncology studies should carefully consider
the time points at which HRQL is measured, in order to
ensure accurate estimates of HRQL can be made both
pre- and post-progression. Investigators should also
examine utility datasets with a clinical rationale for ana-
lyses, and not purely through an economic lens. Whilst
it may be that the progression-based model remains a
good fit for many cancers, this should be shown with
data rather than assumed to be the case.
It is important to note that the effect on the results of
economic modelling when using a time to death ap-
proach (rather than progression-based approach) for
HRQL in a model may be dependent upon the length of
time patients live in a post-progression state. Within the
MDX010-20 dataset, 17% of ipilimumab treated patients
were alive at the end of the 56-month trial period -
nearly all of these in a post-progression state [5]. The
use of a lower utility than these patients experienced (as
would occur when taking the mean utility measurement
for progressive disease) over such a substantial time
period will substantially worsen the modelled cost effect-
iveness of a drug. A time-to-death utility may assign a
lower utility to patients only shortly before death,
thereby increasing the number of modelled quality-
adjusted life years, and potentially altering investment
decisions made as a result. It should be noted, however,
that the cost-effectiveness of treatments would not always
improve, and the results seen would depend on individual
analyses – a treatment with worse post-progression sur-
vival may become less cost-effective.
It is possible that the results seen in MDX010-20 would
not be reproduced in other datasets. The MDX010-20
clinical trial was extremely mature, with approximately
90% of enrolled patients having died on completion at
56 months (giving many data points for analysis). Equally
the underlying disease of melanoma may result in a differ-
ent quality of life profile to solid tumours or haemato-
logical malignancies, which have been more widely
studied. It is also plausible that the results seen were im-
pacted by the treatments used in the MDX010-20
study. In MDX010-20 the control arm was relatively
begin (a vaccine with few side effects, later shown to be
ineffective). The study drug, ipilimumab, has a defined
course of 4 infusions (not on-going treatment, with cor-
responding adverse events), and a relatively good safety
profile. Studies with more toxic chemotherapies includ-
ing frequent administrations (and more aggressive con-
trol arms) may show different results.
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post-progression utility through a delayed response due
to the drug’s mechanism of action – as immunotherapy
ipilimumab acts indirectly on cancer cells via the im-
mune system. This means that patients may progress
before showing a response at which point their symp-
toms (and hence HRQL) improve, owing to the delayed
reaction of treatment [27]. Although the control arm
(gp100) did not show a different pattern to ipilimumab
treatment, this may be due to sample size; four-fifths of
the patients received ipilimumab, either as monotherapy
or in combination with gp100. This delayed reaction
therefore may also be sufficient to cause the relatively
high quality of life on disease progression.Conclusions
This study adds to the body of evidence that suggests alter-
native quality of life measures produce different results.
This can therefore be seen as a validation of the position of
the Scottish Medicines Consortium and NICE in request-
ing a consistent source of utility values [12,29]. The results
seen in this study also indicate further research is needed
on the relationship between the EORTC-8D, SF-6D and
EQ-5D.
In addition, this study demonstrated that utilities based
on time to death appear to provide a good fit to patient
data in the MDX010-20, when compared to utilities based
on disease progression. Practitioners should carefully ana-
lyse HRQL data prior to constructing economic models
based on clinical trials; clinical measures such as disease
progression may not explain quality of life changes, and
an event-based approach may be more suitable.Additional file
Additional file 1: Table S1. Results of regressions showing the impact
of adding melanoma stage, prior interleukin-2, age, and treatment
assignment.
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